He said the program helps companies connect with clinicians who can serve as advisers or help the firms run clinical trials and validation studies and engineers who can solve technical problems as part of the process to make sure any products that come through the program will be viable and broadly accessible to patients. Trey Toombs, head of operations for the IPP, said the program leaders are working with clinicians to identify where new diagnostic tests could improve patient care as well as with the IPP companies to identify how collaborations with clinicians and the Wyss Institute could help them bring new tests to market. Wyss officials see potential that the collaborators can help doctors identify or treat conditions including sepsis and other infectious diseases, cancer, neurological and psychological disorders, chronic pain, and metabolic diseases. "We're building an ecosystem, a repository, a place of helpful resources for anyone working on diagnostics," Ahmad said. Without such guidance to make sure tests work at scale and in the market, many promising advances spend decades between discovery and commercialization - if they make it that far, he said. Rushdy Ahmad, head of the Wyss Diagnostics Accelerator, said the program is meant in part to keep new tests and technologies from dying on the vine by guiding them through biomarker discovery, the development of tests that meet regulatory requirements for specificity and sensitivity, and market guidance to ensure the tests can be sold at prices acceptable to payors. The program is the industry-facing arm of the accelerator, which is meant to match the firms with Brigham and Women's Hospital clinicians and Wyss bioengineers who are developing new tests and testing technologies. NEW YORK – A Harvard University-based diagnostics development program recently emerged from its two-year pilot phase with collaborations already underway to hasten the commercialization of novel testing technologies that could close information gaps in patient care.Ĭalled the Industrial Participant Program and housed within the Wyss Institute for Biologically Inspired Engineering's Diagnostics Accelerator, the initiative has emerged as a full Harvard program with 24 diagnostic companies onboard since being launched as a pilot program in 2021. Advances in Clinical Genomics Profiling. Founded in 2009, and based in Austin, Texas, ActivTrak is backed by Sapphire Ventures and Elsewhere Partners. 5000 and Brandon Hall Excellence in Technology award. More than 9,000 customers trust ActivTrak, which has been recognized by the Deloitte Technology Fast 500, Inc. Our workforce analytics cloud provides visibility and insights across people, processes and technology to help organizations inform key decisions and optimize outcomes. Reworked CONNECT - Innovation Theatre, Expo Hall (Grand Ballroom)ĪctivTrak will demo its workforce analytics platform at Booth #517.ĪctivTrak helps employers and employees work better together to realize their full potential. Javier Aldrete, SVP of Product, ActivTrak This session will discuss how workforce analytics provide valuable insights into employee engagement, productivity and well-being - including how ActivTrak's platform can help answer critical questions, such as: how to define effective remote work policies, identify signs of burnout, optimize workload allocation, and reduce costs in your tech stack and real estate portfolios. Thriving in Tough Times: How to use Workforce Analytics to Drive ResultsĪs companies face economic uncertainty, maximizing workforce efficiency has become a top priority.
0 Comments
Leave a Reply. |